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enucleation is employed quite frequently even at institutions
that do not support its ubiquitous use. These data lay the
groundwork for determining whether RT is a modifiable
variable for functional and oncologic outcomes in patients
who undergo NSS. 
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Aim: The aim of this study was to analyse the intra- and post-
operative complications, as well as the predictive factors of
Trifecta outcome in patients submitted to endoscopic robot-
assisted simple enucleation (ERASE) and open simple
enucleation (OSE) for clinical T1 renal masses. Materials and
Methods: Overall, 634 cases treated with OSE (n=290) and
ERASE (n=344) were prospectively recorded in our
Department between 2006 and 2014. Trifecta was defined as
simultaneous ischemia time <25 min, no surgical
complication and negative surgical margin. A univariate
analysis and multivariate logistic regression were performed
for Trifecta. Results: The two groups were comparable for
body mass index (BMI), comorbidity, tumor side, clinical T
score, tumor diameter, surgical indication, pre-operative renal
function, pre-operative hemoglobin and hematocrit. A
significant difference was found between the OSE and the
ERASE groups in operative time (115 (96-130) vs. 150 (120-
180) minutes, p<0.0001), pedicle clamping (93.8% vs.
69.2%, p<0.0001), estimated blood loss (EBL) (150 (100-
200) vs. 100 (100-143) cc, p<0.0001) and intraoperative
complications (3.4% vs. 1.7%, p=0.02). The two groups were
comparable for warm ischemia time (WIT) ≥25 min. A
significant difference was found between OSE and ERASE
in overall (16.6% vs. 5.5%, p<0.0001), Clavien 2 (11.7% vs.
4.4%, p=0.02) and Clavien 3 (3.1% vs. 1.7%, p=0.04) post-
operative surgical complications, length of stay (6.0 (5.0-7.0)
vs. 5.0 (4.0-6.0) days, p<0.0001), pre-operative 1st day delta
creatinine (0.3 (0.2-0.4) vs. 0.15 (0.1-0.2) mg/dl, p<0.0001),
positive surgical margins (2.1% vs. 1.5%, p=0.04), and
Trifecta achievement (73.8% vs. 85.5%, p<0.0001). At
univariate analysis, a higher median clinical diameter, a
higher mean age, a higher median Charlson comorbidity
index (CCI), endophytic tumor growth pattern, renal sinus
and calyceal dislocation of the tumor, a higher median
PADUA score and OSE were predictive factors of Trifecta
achievement. At multivariate analysis, CCI lost significance
(p=0.26), while age (odds ratio (OR)=1.02, 95% confidence
interval (95% CI)=1.00-1.04, p=0.001), clinical diameter
(OR=1.22, CI=1.05-1.42, p=0.008), PADUA score (OR=1.23,
CI=1.07-1.41, p=0.004) and OSE (OR=1.74, CI=1.13-2.68,
p=0.01) were confirmed predictive factors for Trifecta failure.
Conclusion: The ERASE is a feasible and safe technique,
which shows a comparable WIT, together with a significantly
lower EBL, surgical complications’ rate, length of stay and a
significantly higher Trifecta achievement compared to OSE.
Age, comorbidity, tumor diameter and PADUA score, in
association with surgical approach, represent significant
predictive factors of Trifecta failure.
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Introduction/Aim: Absence of surgical complications represents
an important perioperative goal of partial nephrectomy (PN).
The aim of this study was to analyse intra and post-operative
complications related to nephron-sparing surgery (NSS) in
clinical T1 renal tumors in a wide Italian multicentre dataset
and search for possible predictive factors. Materials and
Methods: Overall, 1,075 patients treated with NSS for clinical
renal tumors, between January 2009 and December 2012, were
prospectively recorded. Overall, X patients had open NSS, Y a
laparoscopic and Z a robotic approach. Centres were divided
in high- and low-volume according to the threshold of 50
interventions per year. A description of cT1 cases (n=965) and
a uni- and multivariate analysis for surgical complication were
performed. Results: Overall, 965 patients were analyzed. 4.9%
had intraoperative complications (3% for pleural injuries, 1%
for vascular injuries, 0.3% for spleen injuries and 0.6% for
other causes). Overall, in 13.3% of patients, post-operative
surgical complications were recoeded (7.6% surgical Clavien
2 and 3.8% surgical Clavien 3). Overall, 6.4% of patients had
post-operative medical complications (3.2% were respiratory,
1.9% cardiologic, 0.2% thromboembolisms and 1.1% for other
causes). At multivariate analysis, ECOG score ≥1 (odds ratio
(OR)=1.9, 95% confidence interval (CI)=1.21-3.10, p=0.01),
clinical diameter (OR=1.42, CI=0.1.07-1.90, p 0.02), open
approach (OR=3.2, CI=1.11-9.30, p 0.03) and estimated blood
loss (EBL) (OR=1.01, CI=1.00-1.01, p 0.01) were significant
predictive factor of surgical post-operative complications. Intra-
operative complications, at univariate analysis, were predictive
factors for surgical post-operative complications (p=0.0001);
however, they did not achieve significance at multivariate
analysis (OR=2.08, CI=0.94-4.59, p=0.07). Conclusion: In this
study, comorbidity status (ECOG score) and clinical diameter
of the tumor were the only pre-operative significant predictive
factors of surgical complications, along with higher EBL and
the open approach. 
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Aim: The aim of this study was to evaluate toxicities and
survival rates of exclusive radiation therapy (RT) in the
treatment of elderly patients with bladder cancer. Matherial and
Methods: Between May 2011 and January 2016, 20 patients
with bladder cancer previously submitted to transurethral
resection (TURB) with diagnosis of high-grade transitional cell
carcinoma, were treated with exclusive RT. Age ranged from
80 to 87 years (median=81). Five patients (25%) presented
stage II disease, 10 (50%) stage II and 5 (25%) stage IV (M0).
A 3-dimensional conformal treatment (3D-CRT) with a four-
field box technique was planned delivering to the pelvis 45 Gy
in 25 fractions with a sequential boost of 22 Gy in 11 fractions
to the bladder and positive nodes for a total dose of 67 Gy.
Acute and late toxicities were evaluated according to RTOG
scale. Results: The median follow-up was 10 months (range=3-
44). Acute genitourinary (GU) toxicity rates were 75%: grade
1/2 and grade 3 were, respectively, 70% and 5%. Grade 1-2
gastrointestinal (GI) toxicity rate was 25%. Grade 1/2 GI late
toxicity rates was 10%. No grade ≥2 toxicity was recorded.
Grade 1 and grade 2 GU late toxicity rate was 35% and 10%,
respectively. No grade ≥3 toxicity was recorded. Overall
survival (OS) was 100% at 2 years and 56% at 3 years. Four
patients died because of systemic disease progression. Five
patients died from intercurrent disease without evidence of
bladder cancer. The actuarial 1-year and 2-year disease-free
survival (DFS) were 59.8% and 33.7%, respectively.
Conclusion: This study demonstrated that in ≥80-year-old
patients, not candidate to surgery or to concomitant radio-
chemotherapy for age and general conditions, exclusive
definitive radiotherapy represents a valid alternative, after
TURB, with acceptable toxicity profile. 
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